Clinical Trials

Enrolling Trials

11-20  of  135
A Randomized Phase II/III Study of the NRG-GY005, Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Evans, Anthony C, Jr.
Ovaries, Uterus, Cervix
Adult
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.
Revels, Cheryl M
(715) 389-4177
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)
Naqvi, Sm Bilal H
Lung - Lung
Adult
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether afatinib dimaleate is more effective when given alone or with cetuximab in treating patients with non-small cell lung cancer.
Bulgrin, Angela M
(715) 221-7261
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI  54868
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Naqvi, Sm Bilal H
Breast
Adult
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to observation in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than observation in treating patients with residual triple negative basal-like breast cancer.
Revels, Cheryl M
(715) 389-4177
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Fagbemi, Seth O
Skin
Adult
This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as v-raf murine sarcoma viral oncogene homolog B V600 (BRAFV600) and cannot be removed by surgery. Ipilimumab and nivolumab may block tumor growth by targeting certain cells. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.
Wight, Molly A
(715) 389-3889
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI  54868
Marshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI  54501
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Abidi, Mateen F
Cardiology - Other
Adult
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).
Mueller, Arika P
(715) 389-7543
Colby/Abbotsford Center
111 Dehne Dr
Colby, WI  54421
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Rhinelander Center
3716 COUNTRY DRIVE
RHINELANDER, WI  54501
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Stratford Center
101 Wisconsin Ave
Stratford, WI  54484
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Fagbemi, Seth O
Kidney Tumors - Renal
Adult
This randomized phase II trial studies how well cabozantinib-s-malate, crizotinib, volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate, crizotinib, volitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Wight, Molly A
(715) 389-3889
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. (MEDI8897 Ph2b)
Sullivan, Michael P
Vaccine - Other
Child
To assess the efficacy of MED18897 when administered as a single 50 mg IM dose to healthy preterm infants born between 29 weeks 0 days and 34 weeks 6 days GA and entering their first RSV season for the reduction of medically attended lower respiratory tract infection due to real time reverse transcriptase-polymerase chain reaction -confirmed RSV, compared to placebo.
Freeman, Sandra K
(715) 387-9059
Salsbery, Cassidy M
(715) 389-4469
A011202, A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Wernberg, Jessica A
Breast
Adult
This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known if radiation therapy alone is as effective as lymph node dissection and radiation therapy together.
Revels, Cheryl M
(715) 389-4177
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Sacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI  54701
St. Michaels Hospital
900 Illinois Ave
Stevens Point, WI  54481
A011502, A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Gayle, Arlene A
Treatment of Side Effects
Breast
Adult
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.
Gamillo, Sarah A
(715) 387-9316
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A031102, A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Mercier, Richard J
Germ Cell Tumors
Stem Cell Transplant - Germ Cell
Adult
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not yet known whether high-dose combination chemotherapy and stem cell transplant are more effective than standard-dose combination chemotherapy in treating patients with refractory or relapsed germ cell tumors.
Bredeck, Tiffany M
(715) 389-4773